Cargando…

Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report

With the extensive use of immune checkpoint inhibitors (ICI) in advanced-stage cancers, immune-related adverse events (irAEs) have been noted in various systems. While most irAEs are reversible and manageable, cardiac toxicities are rare but life-threatening, with high mortality rates. We present a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Yunyao, Li, Yiping, Zhang, Sihui, Han, Gaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620143/
https://www.ncbi.nlm.nih.gov/pubmed/36300305
http://dx.doi.org/10.1177/03000605221133259
_version_ 1784821315700523008
author Ye, Yunyao
Li, Yiping
Zhang, Sihui
Han, Gaohua
author_facet Ye, Yunyao
Li, Yiping
Zhang, Sihui
Han, Gaohua
author_sort Ye, Yunyao
collection PubMed
description With the extensive use of immune checkpoint inhibitors (ICI) in advanced-stage cancers, immune-related adverse events (irAEs) have been noted in various systems. While most irAEs are reversible and manageable, cardiac toxicities are rare but life-threatening, with high mortality rates. We present a case of a 71-year-old man with cholangiocarcinoma who developed myocarditis related to ICIs 29 days after the first infusion of teriprizumab combined with albumin-bound paclitaxel and gemcitabine. He was initially asymptomatic after admission but with substantial elevations of troponin I and myocardial enzymes. Sixteen hours after admission, he developed palpitations, dizziness, and syncope. Electrocardiography confirmed third-degree atrioventricular block and frequent ventricular premature contractions for which he received high-dose corticosteroids and a permanent pacemaker. The patient survived and permanently discontinued immunotherapy. Early identification and intervention are the keys to improving the prognosis of immune myocarditis.
format Online
Article
Text
id pubmed-9620143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96201432022-11-01 Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report Ye, Yunyao Li, Yiping Zhang, Sihui Han, Gaohua J Int Med Res Case Reports With the extensive use of immune checkpoint inhibitors (ICI) in advanced-stage cancers, immune-related adverse events (irAEs) have been noted in various systems. While most irAEs are reversible and manageable, cardiac toxicities are rare but life-threatening, with high mortality rates. We present a case of a 71-year-old man with cholangiocarcinoma who developed myocarditis related to ICIs 29 days after the first infusion of teriprizumab combined with albumin-bound paclitaxel and gemcitabine. He was initially asymptomatic after admission but with substantial elevations of troponin I and myocardial enzymes. Sixteen hours after admission, he developed palpitations, dizziness, and syncope. Electrocardiography confirmed third-degree atrioventricular block and frequent ventricular premature contractions for which he received high-dose corticosteroids and a permanent pacemaker. The patient survived and permanently discontinued immunotherapy. Early identification and intervention are the keys to improving the prognosis of immune myocarditis. SAGE Publications 2022-10-27 /pmc/articles/PMC9620143/ /pubmed/36300305 http://dx.doi.org/10.1177/03000605221133259 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Reports
Ye, Yunyao
Li, Yiping
Zhang, Sihui
Han, Gaohua
Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title_full Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title_fullStr Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title_full_unstemmed Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title_short Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
title_sort teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620143/
https://www.ncbi.nlm.nih.gov/pubmed/36300305
http://dx.doi.org/10.1177/03000605221133259
work_keys_str_mv AT yeyunyao teriprizumabinducedmyocarditisinapatientwithcholangiocarcinomaacasereport
AT liyiping teriprizumabinducedmyocarditisinapatientwithcholangiocarcinomaacasereport
AT zhangsihui teriprizumabinducedmyocarditisinapatientwithcholangiocarcinomaacasereport
AT hangaohua teriprizumabinducedmyocarditisinapatientwithcholangiocarcinomaacasereport